Clinical Trial Update: Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update indicates that the intravenous agent YM087, sponsored by Cumberland Pharmaceuticals, completed a study assessing its efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia

Drugs mentioned

• YM087

Snippet

Sponsor: Cumberland Pharmaceuticals | Conditions: Hyponatremia | Phase 3 | Status: COMPLETED